Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesNephrologyBlue Cross Blue Shield Iowa Kerendia Coverage Upda…
    Ask Trek AI about this page
    ModifiedBlue Cross Blue Shield - IowaPolicy 05.04.97

    Kerendia (finerenone) — Coverage Criteria

    Customize your policy alerts

    Sign up for Blue Cross Blue Shield - Iowa Policy 05.04.97 alerts

    Get alerted when Policy 05.04.97 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and medical necessity criteria for coverage of Kerendia (finerenone) for adults with chronic kidney disease and type 2 diabetes or heart failure, per Blue Cross Blue Shield - Iowa.

    Policy Summary
    PayerBlue Cross Blue Shield - Iowa
    PolicyKerendia (finerenone) — Coverage Criteria
    Policy CodePolicy 05.04.97
    Change TypeReviewed and revised
    Effective DateAug 5, 2026
    Next Review DateJun 1, 2026
    Key ActionSubmit prior authorization documenting CKD with T2D or HF, baseline ACEi/ARB and SGLT2 use or documented intolerance/contraindication, and relevant labs (eGFR, UACR, potassium).
    SourceLink
    POLICY UPDATE CHANGES

    Reviewed and revised in June 2026 with a current effective date of August 5, 2026.

    12 monthstypical approval duration
    ≥25minimum eGFR
    ≤5 mEq/LK+ threshold (init)
    ≤5.5 mEq/LK+ threshold (cont)

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Adults w/ CKD & T2Dindicated population
    Jun 2026last review

    Coverage and Medical Necessity Criteria

    Initial Therapy — CKD and T2DM

    Covered when ALL of the following are met for CKD with T2DM (Initial Approval):

    CKD and T2DM Initial: 1. Diagnosis of chronic kidney disease (CKD).
    CKD and T2DM Initial: 2. History of type 2 diabetes mellitus (T2DM).
    CKD and T2DM Initial: 3. Age >= 18 years.
    CKD and T2DM Initial: 4. Currently receiving a maximally tolerated dose of an ACE inhibitor (ACEi) or angiotensin receptor blocker (ARB) OR has documented intolerance, allergy, or contraindication to an ACEi or ARB.

    CKD and T2DM Initial - Lab criteria

    • a: Urinary albumin-to-creatinine ratio (UACR) >= 30 mg/g (>= 3 mg/mmol).>= 30 mg/g (>= 3 mg/mmol)
    • b: An estimated glomerular filtration rate (eGFR) >= 25 ml/min/1.73 m2.>= 25 ml/min/1.73 m2
    • c: Serum potassium <= 5 mEq/L.<= 5 mEq/L

    Initial Therapy — Heart Failure

    Covered when ALL of the following are met for Heart Failure (Initial Approval):

    HF Initial: 1. Diagnosis of heart failure (HF).
    HF Initial: 2. Left ventricular ejection fraction (LVEF) >= 40%.>= 40%
    HF Initial: 3. Age >= 18 years.

    HF Initial - Lab criteria

    • a: An eGFR >= 25 ml/min/1.73 m2.>= 25 ml/min/1.73 m2

    Continuation Therapy — CKD and T2DM

    Covered when ALL of the following are met for CKD with T2DM (Continuation):

    CKD and T2DM Continuation: 1. Member is experiencing clinical improvement with the requested agent.
    CKD and T2DM Continuation: 2. Currently receiving a maximally tolerated dose of an ACE inhibitor (ACEi) or ARB OR has documented intolerance, allergy, or contraindication to an ACEi or ARB.
    CKD and T2DM Continuation - Lab: 3. Serum potassium level <= 5.5 mEq/L.<= 5.5 mEq/L

    Approval duration: 12 months

    Continuation Therapy — Heart Failure

    Covered when ALL of the following are met for Heart Failure (Continuation):

    HF Continuation: 1. Member is experiencing clinical improvement with the requested agent.
    HF Continuation - Lab: 2. Serum potassium level <= 5.5 mEq/L.<= 5.5 mEq/L

    Approval duration: 12 months

    Initial coverage criteria (Kerendia for CKD with T2D)

    Covered when ALL of the following are met

    Indication: Patient is an adult with chronic kidney disease (CKD) associated with type 2 diabetes (T2D).

    Indication aligns with FDA labeling and clinical rationale

    Background therapy or contraindication: Patient is receiving concomitant ACE inhibitor or ARB and an SGLT2 inhibitor, OR has documented intolerance or contraindication to an ACE inhibitor or ARB and an SGLT2 inhibitor.

    Policy states coverage will be considered when concomitant therapy or documented intolerance/contraindication exists

    Kidney function: Patient has eGFR >= 25 ml/min/1.73 m2 and normal serum potassium per guideline context.eGFR >= 25 ml/min/1.73 m2

    Guideline-referenced threshold for ns-MRA use

    Members who fail to meet the specific clinical criteria detailed above are considered not eligible for coverage. This includes members who do not have the required diagnosis, do not meet the laboratory thresholds (for example, eGFR ≥ 25 ml/min/1.73 m2 or the applicable serum potassium thresholds), or who lack documentation of required concomitant therapy or documented intolerance/contraindication. Members receiving Kerendia as samples or through the manufacturer's patient assistance program must still meet the criteria for initial approval to be covered.

    None explicitly listed in this section of the policy.

    Kerendia is considered not medically necessary for members who do not meet the specified initial or continuation approval criteria set forth in this policy. This determination applies when required diagnostic criteria, age, laboratory thresholds, or documentation of background therapy (or documented intolerance/contraindication) are not provided.

    Coverage consideration for Kerendia assumes either concomitant use of an ACE inhibitor or ARB and an SGLT2 inhibitor or clear documentation of intolerance or contraindication to those agents. In the absence of documentation showing the patient is receiving these concomitant therapies or has an intolerance/contraindication, coverage may be denied. Providers should therefore document current background therapies or the clinical rationale for not using them.

    Billing and Clinical Thresholds

    Billing and coding referencesmixed
    CPT (general)Appropriate CPT codes to report provider services as applicable (document references CPT use but does not list specific codes)
    HCPCS (Alpha Numeric level II)Use appropriate HCPCS level II codes where applicable (document references HCPCS use but does not list specific codes)
    RevenueUse appropriate revenue codes as applicable
    ICD-10Use appropriate ICD diagnostic codes as applicable
    NDCDrug NDC codes for Kerendia (finerenone) as applicable
    eGFR — threshold reference
    eGFR threshold>= 25 ml/min/1.73 m2
    ContextReferenced for consideration of ns-MRA use in patients with T2D and CKD
    Applies toInitial coverage for CKD with T2DM and HF initial criteria (see policy sections)
    serum potassium (initiation)
    Serum potassium (initiation)<= 5 mEq/L
    Applies toInitial therapy for CKD with T2DM and Heart Failure initial approval
    Source note

    Prior Authorization and Documentation Requirements

    Prior Authorization

    Prior authorization required

    Prior authorization is required for Kerendia; approvals are granted only when the submitted request meets the applicable initial or continuation clinical criteria (diagnosis, age, eGFR, serum potassium, concomitant ACEi/ARB status, and UACR for CKD with T2D).

    Prior Authorization

    Prior authorization must confirm indication and background therapy

    Submit a prior authorization that documents the patient has CKD associated with type 2 diabetes and includes verification of concomitant ACEi/ARB and SGLT2 use or documented intolerance/contraindication; include appropriate billing codes (CPT/HCPCS/ICD or NDC as applicable).

    Step Therapy

    Document ACEi/ARB status and SGLT2 context

    Drug Background and Evidence Summary

    Kerendia (finerenone) is a selective nonsteroidal mineralocorticoid receptor antagonist (ns-MRA) indicated to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular events in adults with chronic kidney disease associated with type 2 diabetes. Phase 3 trials (FIDELIO-DKD and FIGARO-DKD) demonstrated kidney and cardiovascular benefits when finerenone was added to standard therapy, and guideline consensus recommends ns‑MRA use in patients with T2D and CKD who have eGFR ≥ 25 ml/min/1.73 m2, normal serum potassium, and persistent albuminuria despite maximally tolerated ACEi or ARB therapy.

    Key Definitions and Terms

    FDA-approved indications
    FDA indication — CKD with T2DMReduce risk of eGFR decline, end-stage kidney disease, CV death, non-fatal MI, and hospitalization for HF in adults with CKD and T2DM
    FDA indication — Heart FailureReduce risk of cardiovascular death, hospitalization for HF, and urgent HF visits in adults with HF with LVEF >=40%
    PopulationAdults meeting the specified disease criteria per labeling
    ns-MRA (definition)
    DefinitionNonsteroidal mineralocorticoid receptor antagonist (ns-MRA) with demonstrated kidney and cardiovascular benefits in phase 3 trials
    Clinical relevanceClass includes agents added to standard therapy for T2D with CKD to reduce progression and CV events

    Policy Revision History

    2026-08-05effective_dateLatest

    Policy current effective date updated to August 5, 2026 after June 2026 review and revision.

    2026-06review_and_revision

    Policy was reviewed and revised in June 2026 (per policy history).

    2023-08-01original_effective_date
    Policy Summary
    PayerBlue Cross Blue Shield - Iowa
    PolicyKerendia (finerenone) — Coverage Criteria
    Policy CodePolicy 05.04.97
    Change TypeReviewed and revised
    Effective DateAug 5, 2026
    Next Review DateJun 1, 2026
    Key ActionSubmit prior authorization documenting CKD with T2D or HF, baseline ACEi/ARB and SGLT2 use or documented intolerance/contraindication, and relevant labs (eGFR, UACR, potassium).
    SourceLink
    On This Page
    Coverage and Medical Necessity CriteriaBilling and Clinical ThresholdsPrior Authorization and Documentation RequirementsDrug Background and Evidence SummaryKey Definitions and TermsPolicy Revision History
  1. b: A serum potassium level <= 5 mEq/L.<= 5 mEq/L
  2. Explicit initiation threshold stated in CKD/T2DM and HF initial criteria
    serum potassium (continuation)
    Serum potassium (continuation)<= 5.5 mEq/L
    Applies toContinuation therapy criteria for CKD with T2DM and Heart Failure
    Source noteContinuation sections list the higher allowable serum potassium threshold
    UACR (urinary albumin-to-creatinine ratio)
    UACR threshold>= 30 mg/g (>= 3 mg/mmol)
    Applies toInitial CKD with T2DM coverage (must meet all listed criteria)
    MeasurementUrinary albumin-to-creatinine ratio used to define albuminuria in policy
    age
    Minimum age>= 18 years
    Applies toAll initial therapy criteria for CKD with T2DM and Heart Failure
    Regulatory noteFDA-approved indications and policy both refer to adult patients
    eGFR threshold (alternate placement)
    Alternate eGFR reference>= 25 ml/min/1.73 m2
    Guideline contextReferenced by ADA/KDIGO consensus recommending ns-MRA for patients with eGFR >=25 and albuminuria despite ACEi/ARB
    UseApplied when assessing eligibility for ns-MRA (finerenone) per clinical rationale

    Document that the member is receiving a maximally tolerated dose of an ACE inhibitor or ARB, or that there is an intolerance, allergy, or contraindication to ACEi/ARB; policy references use of Kerendia alongside SGLT2 inhibitor therapy per clinical guidance.

    • For CKD with T2D initial and continuation criteria, ACEi/ARB status (maximally tolerated or intolerance/contraindication) is required (see criteria).
    • Clinical rationale supports addition of ns‑MRA when albuminuria persists despite maximal ACEi/ARB and in the context of SGLT2 therapy.
    Step Therapy

    Document persistent albuminuria and SGLT2 context

    When albuminuria persists despite a maximally tolerated ACEi or ARB, document current SGLT2 therapy or reason it is not used; policy supports Kerendia use in patients with persistent albuminuria despite ACEi/ARB and in the context of SGLT2 therapy.

    • For CKD with T2D initial approval, record UACR ≥ 30 mg/g (≥3 mg/mmol) and eGFR ≥ 25 ml/min/1.73 m2.
    • State whether the patient is taking an SGLT2 inhibitor or provide documentation of intolerance/contraindication if not.
    Note

    Verify member benefits and contract applicability

    Verify individual member benefits and applicable contract language at the time of service; exclusions, limitations, or exceptions may apply and benefits may vary by contract.

    • Benefit verification is required before assuming coverage; Wellmark determines medical necessity only if the benefit exists and no contract exclusions apply.
    Documentation Required

    Documentation: diagnosis, baseline therapies, labs, and intolerance/contraindication

    Include documentation of the diagnosis (CKD associated with T2D or heart failure as applicable), baseline therapies (current ACEi/ARB and SGLT2 inhibitor), or clear documentation of intolerance/contraindication to those agents; provide relevant labs (UACR, eGFR, serum potassium) aligned to the criteria.

    • For CKD with T2D initial approval: UACR ≥ 30 mg/g (≥3 mg/mmol), eGFR ≥ 25 ml/min/1.73 m2, and serum potassium ≤ 5 mEq/L.
    • For continuation: document clinical improvement and serum potassium ≤ 5.5 mEq/L.
    • Use appropriate CPT/HCPCS/ICD codes when submitting claims.
    Denial Risk

    Denial risk when criteria are not met

    Kerendia will be considered not medically necessary and may be denied when the member does not meet the specified initial or continuation criteria (including diagnosis, age, required lab thresholds, or documented background therapy/intolerance).

    • Members receiving samples or manufacturer assistance must also meet initial approval criteria.
    • Absence of documentation of ACEi/ARB and SGLT2 use (or intolerance/contraindication) may lead to non-coverage.
    Note

    Coverage when concomitant therapy present or intolerance/contraindication documented

    Coverage may be granted when the patient is receiving concomitant ACEi/ARB and SGLT2 therapy or when there is documented intolerance or contraindication to those agents; include documentation of the intolerance/contraindication or current concomitant therapy in the prior authorization.

    • Policy language: coverage will be considered in patients receiving concomitant therapy with, who have experienced intolerance to, or have a contraindication to an ACEi or ARB and an SGLT2 inhibitor.
    • Provide clear documentation of concomitant medications or clinical rationale for withholding them.
    Example trialsBenefits described in FIDELIO-DKD and FIGARO-DKD
    ns-MRA (example: finerenone)
    Example agentFinerenone (Kerendia)
    RoleSelective, nonsteroidal MRA shown to reduce kidney and cardiovascular outcomes in adults with CKD and T2D
    Clinical evidencePhase 3 studies (FIDELIO-DKD, FIGARO-DKD) support finerenone's efficacy
    eGFR definition
    DefinitionEstimated glomerular filtration rate (eGFR), used to assess kidney function
    Policy threshold>= 25 ml/min/1.73 m2 referenced for ns-MRA consideration and coverage criteria
    ApplicationUsed in initial and guideline-based eligibility assessments for Kerendia

    Policy originally became effective August 1, 2023.